Q2
BEAM — Q2 2026 Financial Report Analysis
Beam Therapeutics' partner revenue fell to $0.5M and its net loss widened 20% to $122.7M ($1.18/share) as costs held flat; $1.15B of cash plus planned loan draws funds it into mid-2029, with a risto-cel FDA filing targeted for year-end.